FEB 2 0 2009 F

PTO/SB/08a (11-08)
Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) set 1 of 4	Complete if Known			
Jul		Application Number	10/809,689-Conf. #7876		
IN		SCLOSURE	Filing Date	March 25, 2004	
				First Named Inventor	Mark LARCHE
Ŭ				Art Unit	1644
	(Use as many sh	eets a	s necessary)	Examiner Name	N. M. Rooney
Sheet	et 1 of 4		4	Attorney Docket Number	JKJ-005CNRCE

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1*	US-4,163,778	08-07-1979	Ohman et al.			
	A2*	US-4,338,297	07-06-1982	Michael et al.			
			<u> </u>				
	 						
	 						

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т6
	B1	WO-91/06571-A1	05-16-1991	Immulogic Pharmaceutical Corporation		
	B2	WO-92/15613-A1	09-17-1992	Immulogic Pharmaceutical Corporation		
	В3	WO-93/08280-A1	04-29-1993	Immulogic Pharmaceutical Corporation		
	B4	WO-93/19178-A2	09-30-1993	Immunologic Pharmaceutical Corporation		
						_

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No. EM194128615US

Dated: February 20, 2009

PTO/SB/08b (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known			
	FORMATION DISCLOSURE TATEMENT BY APPLICANT		Application Number 10/809,689-Conf. #7876		
11	IFORMATION	ATEMENT BY APPLICAN		Filing Date	March 25, 2004
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	Mark LARCHE
				Art Unit	1644
				Examiner Name	N. M. Rooney
Sheet	heet 2 of 4		Attorney Docket Number	JKJ-005CNRCE	

	_	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	$\overline{}$
Examiner Initials	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Anderson, M.C. et al., "A comparative study of the allergens of cat urine, serum, saliva, and pelt," <i>J. Allergy Clin. Immunol.</i> , Vol. 76:563-569 (1985)	
	C2	Chapman, Martin D. et al., "Monoclonal Antibodies to the Major Feline Allergen Fel d I II. Single Step Affinity Purification of Fel d I, N-Terminal Sequence Analysis, and Development of a Sensitive Two-Site Immunoassay to Assess Fel d I Exposure," The Journal of Immunology, Vol. 140:812-818 (1988)	
	СЗ	de Groot, Hans et al., "Monoclonal antibodies to the major feline allergen Fel d I," J. Allergy Clin. Immunol., Vol. 82:778-786 (1988)	
	C4	Didierlaurent, A. et al., "Comparative Study on Cat Allergens from Fur and Saliva," <i>Int. Archs. Allergy appl. Immun.</i> , Vol. 73:27-31 (1984)	
	C5	Duffort, O. et al., "Characterization of the main IgE-binding components of cat dander," Int. Arch. Allergy Appl. Immunol., Vol. 84(4):339-344 (1987)	
	C6	Duffort, Oscar et al., "Monoclonal antibodies against Fel d I and other clinically relevant cat allergens," <i>Immunology Letters</i> , Vol. 17:71-77 (1988)	
	C7	Jenkins, Marc K. et al., "Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo," <i>Journal of Experimental Medicine</i> , Vol. 165:302-319 (1987)	
	C8	Leitermann, Kathleen et al., "Cat allergen 1: Biological, antigenic, and allergenic properties," J. Allergy Clin. Immunol., Vol. 74:147-153 (1984)	
	C9	Lerner, Richard A., "Tapping the immunological repertoire to produce antibodies of predetermined specificity," <i>Nature</i> , Vol. 14:592-596 (1982)	
	C10	Løwenstein, H. et al., "Identification and Clinical Significance of Allergenic Molecules of Cat Origin," <i>Allergy,</i> Vol. 40:430-441 (1985)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number 10/809,689-Conf. #7876			
II.	FORMATION DISCLOSURI ATEMENT BY APPLICAN (Use as many sheets as necessary)	SCLOSURE	Filing Date March 25, 2004			
S	STATEMENT BY APPLICANT			First Named Inventor	Mark LARCHE	
				Art Unit	1644	
	(Use as many sh	eets as	necessary)	Examiner Name	N. M. Rooney	
Sheet	1 0 1 1		4	Attorney Docket Number	JKJ-005CNRCE	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T²
Initials	NO.	number(s), publisher, city and/or country where published.	
	C11	Margalit, Hanah et al., "Prediction of Immunodominant Helper T Cell Antigenic Sites from the Primary Sequence," <i>The Journal of Immunology,</i> Vol. 138:2213-2229 (1987)	
	C12	Mester, Joseph C. et al., "The Mouse Model and Understanding Immunity to Herpes Simplex Virus," Reviews of Infectious Diseases, Vol. 13(Suppl. 11):S935-S945 (1991)	
	C13	Michael, J.G. et al., "Modulation of the immune response to ragweed allergens by peptic fragments," Clinical and Experimental Allergy, Vol. 20:669-674 (1990)	
	C14	Morgenstern, Jay P. et al., "Amino acid sequence Fel dl, the major allergen of the domestic cat: Protein sequence analysis and cDNA cloning," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 88:9690-9694 (1991)	
	C15	Ohman, John L. Jr. et al., "Allergens of Mammalian Origin III. Properties of a Major Feline Allergen," <i>The Journal of Immunology,</i> Vol. 113(6):1668-1677 (1974)	
	C16	Ohman, J.L. Jr. et al., "Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses," <i>J. Allergy Clin. Immunol.</i> , Vol. 74:230-239 (1984)	
	C17	Ota, Kohei et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis," <i>Nature</i> , Vol. 346:183-187 (1990)	
	C18	Rothbard, Jonathan B. et al., "A sequence pattern common to T cell epitopes," <i>The EMBO Journal</i> , Vol. 7(1):93-100 (1988)	
	C19	Sundin, B. et al., "Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma," <i>J. Allergy Clin. Immunol.</i> , Vol. 77(3):478-487 (1986)	
	C20	Unanue, Emil R. et al,. "Immediate Hypersensitivity Reactions and Anaphylaxis," <i>Textbook of Immunology,</i> 2nd Edition, Williams & Wilkins, Chpt. 14, pgs. 281-298 (1984)	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b.(11-08)
Approved for use through 12/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known				
		DRMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/809,689-Conf. #7876	
11	NFORMATION	N DIS	CLOSURE	Filing Date	March 25, 2004	
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Mark LARCHE	
				Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	N. M. Rooney	
Sheet	4	of	4	Attorney Docket Number	JKJ-005CNRCE	

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	van Milligen, Florine J. et al., "IgE Epitopes on the Cat Allergen Fel d I: A Study with Overlapping Synthetic Peptides," CLB and Lab Epl. Clin. Immunol., University of Amsterdam, Abstracts Vol. 89(1 pt. 2):243, No. 393 (1992)	
	C22	Wucherpfennig, Kai W. et al., "Structural Requirements for Binding of an Immunodominant Myelin Basic Protein Peptide to DR2 Isotypes and for Its Recognition by Human T Cell Clones," J. Exp. Med., Vol. 179:279-290 (1994)	
	C23	Young, Richard A. et al., "Efficient isolation of genes by using antibody probes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80:1194-1198 (1983)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.